ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

2015 ASCO Genitourinary Cancer Symposium

2015 ASCO Genitourinary Cancer Symposium

Inherited variants in an androgen transporter gene may determine the time to progression (TTP) for men with prostate cancer receiving androgen deprivation therapy (ADT).

A significant progression-free survival and overall response rate improvement was seen in patients with advanced urothelial carcinoma treated with the combination of the VEGFR-2 antagonist ramucirumab (Cyramza) plus docetaxel.

Patients with sarcomatoid or poor-risk renal cell carcinoma (RCC) had frequent objective responses when treated with the combination of gemcitabine (Gemzar) and sunitinib (Sutent), according to the results of a small phase II study.

Identifying gene signatures in patients with clear cell renal cell carcinoma (ccRCC) that can predict the likelihood of their disease metastasizing, as well as the site of metastasis, may help to better stratify risk assessment for the disease and plan appropriate treatment strategies.

Neither sunitinib nor sorafenib reduced disease recurrence in patients with locally advanced renal cell carcinoma (RCC) when these agents were given to patients as adjuvant therapy, according to the results of a new study.

Subscribe to 2015 ASCO Genitourinary Cancer Symposium on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.